Agoracom: Small Cap Investment - Resverlogix Corp. - Cleveland Clinic's Nissen says CETP inhibition unlikely to work

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Back To Forum List View

Lilly to Discontinue Development of Evacetrapib

tundup

Oct 12, 2015 08:54AM

Re: Lilly to Discontinue Development of Evacetrapib

tundup

Oct 12, 2015 09:58AM

tundup

Rank: Treasurer [?]

Points: 421 [?]

Votes: 16 Score: 3.6 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Cleveland Clinic's Nissen says CETP inhibition unlikely to work

in response to

Re: Lilly to Discontinue Development of Evacetrapib

tundup

posted on Oct 12, 2015 10:13AM

Looks like he is really sticking the knife in. "Lilly's Evacetrapib best ever in biological effect" "Very unlikely other CETP inhibitors will work". I bet Merck is pleased with those comments!

5 Recommendations

Re: Cleveland Clinic's Nissen says CETP inhibition unlikely to work

Spring Salmon

Oct 12, 2015 03:21PM

Re: Cleveland Clinic's Nissen says CETP inhibition unlikely to work

Jkj193741

Oct 12, 2015 03:46PM

Re: Cleveland Clinic's Nissen says CETP inhibition unlikely to work

Jkj193741

Oct 12, 2015 04:01PM

Re: Lilly to Discontinue Development of Evacetrapib

fouremm